Sysmex & ZECEN signed a strategic cooperation agreement on March 9,2023

Sysmex

zecen biotech

advantage Have advanced quality management system and developed marketing network more than 100 kinds of biochemical immunoassay reagent products

weak point The subdivision of biochemical immunity needs to be further enriched as a rapidly growing young company, both the management and marketing systems are facing growing pains

After cooperation Realize the three in vitro diagnostic subdivisions of biochemical immunity, clinical testing, and microbiology to keep pace, while further improving R&D efficiency, reducing R&D costs, and making a greater strategic layout globally many detection reagent products can be rapidly expanded through the extensive market network of sysmex, and the production management and quality control systems will also be upgraded simultaneously, thereby accelerating the expansion and strengthening

latest company news about sysmex & ZECEN signed a strategic cooperation agreement on March 9,2023 

The combination of the two has a special significance for Zecen Biotech.

This strategic cooperation is not an ordinary "linear integration" of the upstream and downstream of the industrial chain, but an "inyter-embedded" "industrial synergy". Through CDMO, Zecen has provided customized R&D and production outsourcing services for sysmex. The core of this service is that the service provider must have the core capability of technological innovation.

"This strategic cooperation, on the one hand, means that zecen's innovative ability has gained higher recognition, on the other hand, it also means that zecen has added the" engine "of service outsourcing business while developing its own business, and entered the" dual engine "development era.

sysmex & ZECEN signed a strategic cooperation agreement on March 9,2023

March 9，2023
Jiangsu Zecen Biotech Co., Ltd. and the international leader in in vitro diagnostics - Japan sysmex Co., Ltd. launched a strategic cooperation in China Medical City.
Carry out gear-type complementary cooperation in the field of biochemical immunology of in vitro diagnostic reagents with the emerging CDMO model.
This is the first case in this subdivided field in China!

In vitro diagnosis refers to products and services that obtain clinical diagnostic information by testing human samples (blood, body fluids, tissues, etc.) outside the human body, and then determine diseases or body functions. Known as the "doctor's eyes", it is the basis for medical decision-making such as clinical medical diagnosis, treatment and prevention.

Bright future for in vitro diagnostics industry

According to statistics, the current global in vitro diagnostic market size is nearly 80 billion U.S. dollars, and China’s is nearly 18 billion U.S. dollars. With the aging population, the market space will continue to expand.

sysmex

sysmex is a multinational company, founded in 1968, headquartered in Kobe, Japan, with more than 70 branches all over the world, and its products are distributed in more than 190 countries and regions. The company ranks sixth in the global in vitro diagnostics industry, with revenue exceeding US$800 million in 2022.

ZECEN biotech

Founded in 2011, Zecen biotech is an in vitro diagnostic company mainly focusing on fully automatic chemiluminescent products. It has intellectual property rights related to the tubular magnetic particle chemiluminescent immunoassay intelligent diagnostic system, and has obtained a number of invention patents, and is developing rapidly.

Sysmex

zecen biotech

advantage Have advanced quality management system and developed marketing network more than 100 kinds of biochemical immunoassay reagent products

weak point The subdivision of biochemical immunity needs to be further enriched as a rapidly growing young company, both the management and marketing systems are facing growing pains

After cooperation Realize the three in vitro diagnostic subdivisions of biochemical immunity, clinical testing, and microbiology to keep pace, while further improving R&D efficiency, reducing R&D costs, and making a greater strategic layout globally many detection reagent products can be rapidly expanded through the extensive market network of sysmex, and the production management and quality control systems will also be upgraded simultaneously, thereby accelerating the expansion and strengthening.

Latest company news about sysmex & ZECEN signed a strategic cooperation agreement on March 9,2023  1

The combination of the two has a special significance for Zecen Biotech.

This strategic cooperation is not an ordinary "linear integration" of the upstream and downstream of the industrial chain, but an "inyter-embedded" "industrial synergy". Through CDMO, Zecen has provided customized R&D and production outsourcing services for sysmex. The core of this service is that the service provider must have the core capability of technological innovation.

"This strategic cooperation, on the one hand, means that zecen's innovative ability has gained higher recognition, on the other hand, it also means that zecen has added the" engine "of service outsourcing business while developing its own business, and entered the" dual engine "development era.